Yıl: 2016 Cilt: 50 Sayı: 3 Sayfa Aralığı: 171 - 180 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation

Öz:
Primer Hiperparatiroidi: Klinik ve biyokimyasal bulguların güncel durumuPrimer hiperparatiroidizm (pHPT) en sık 3. endokrin hastalıktır ve ayaktan hastalarda hiperkalseminin en sık sebebidir. Geçmişte hastaların çoğu belirgin pHPT semptom ve bulguları ile başvurmaktaydılar. Otomatik kan analizörlerinin gelişmesi ve yaygın kullanılması ile günümüzde hastaların büyük bölümü diğer nedenlerle yapılan rutin biyokimyasal testlerle teşhis edilmektedir. Hastaların çoğunluğu minimal semptomatik veya asemptomatiktir. pHPT'nin klinik prezentasyonu, asemptomatik hastalıktan renal ve iskelet komplikasyonlarının gözlendiği semptomatik hastalığa kadar değişir. Hafif pHPT terimi 30 yıldır birçok farklı durum için kullanılmıştır. Hafif pHPT terimi net olarak, güncellenen uluslararası kılavuzlara göre cerrahi endikasyonu olmayan asemptomatik hastaları belirtmek için tanımlanmıştır. Normokalsemik pHPT ilk olarak 2008'de asemptomatik pHPT'nin tedavisi ile ilgili düzenlenen 3. uluslararası çalıştayda resmen kabul edilmiştir. Normokalsemik pHPT klasik hiperkalsemik pHPT'nin bir varyantıdır. Normokalsemik pHPT paratiroid hormon (PTH) artışına neden olabilecek sekonder bir sebep olmaksızın, normal iyonize ve total kalsiyum (Ca) düzeyleri ile birlikte yüksek PTH düzeyi ile karakterizedir. pHPT biyokimyasal olarak klasik pHPT (hem Ca hem PTH yüksek), nonklasik (normohormonal veya nonsuprese) pHPT (yüksek Ca, normal PTH), normokalsemik pHPT (normal Ca, yüksek PTH) olarak prezente olabilir. pHPT'nin tek küratif tedavisi cerrahidir. Paratiroidektomi bütün semptomatik hastalarda endikedir. Asemptomatik pHPT'nin tedavisi ile ilgili 4. uluslararası çalıştay 2013'te yapıldı. pHPT'nin cerrahi endikasyonları yaş, Ca düzeyi, iskelet ve böbrek bulgularına göre belirlenir. Bazı asemptomatik hastalarda cerrahi zorunlu değildir. Diğer yandan, paratiroidektomi için cerrahi kriterleri olmayan bu hastalarda bile cerrahi daima bir seçenektir. Çünkü cerrahi, pHPT'nin tek kesin tedavisidir. Normokalsemik pHPT'li hastaların optimal tedavi stratejisi halen ortaya koyulamamıştır. Bu konunun deneyimli uzmanları Ca düzeyi normal devam etse bile osteoporoz, fraktür, böbrek taşı gibi pHPT kopmplikasyonlarının varlığında veya bunların ortaya çıkmasında cerrahi önermektedirler. Tanı anında komplikasyonsuz hastalar hastalık ilerlemesi için takip edilebilir.
Anahtar Kelime:

Konular: Cerrahi

Primer Hiperparatiroidi: Klinik ve biyokimyasal bulguların güncel durumu

Öz:
Primary hyperparathyroidism: Current situation in the clinical and biochemical presentation Primary hyperparathyroidism (pHPT) is the third most common endocrine disease and the most common cause of outpatient hypercalcemia. Historically, most patients presented with overt symptoms and signs of pHPT. With the advent and widespread use of automated blood analyzers, currently the majority of patients are diagnosed through routine biochemical laboratory testing done for other aims. The majority of patients are minimally symptomatic or asymptomatic. The clinical presentation of pHPT varies from asymptomatic disease to classic symptomatic disease in which renal and/or skeletal complications are observed. The term "mild pHPT" has been interpreted in many different ways over the past 30 years. Mild pHPT was clearly defined as a disease in asymptomatic patients who do not meet surgical criteria set out by the updated International Guidelines. Normocalcemic pHPT was first defined formally at the time of the ''Third International Workshop on the Management of Asymptomatic pHPT'' in 2008. Normocalcemic pHPT, a variant of the traditional hypercalcemic presentation of pHPT, is characterized by consistently elevated PTH concentrations with normal total and ionized serum calcium (Ca) concentration in the absence of secondary causes for elevated PTH concentrations. Primary hyperparathyroidism may present as classic pHPT (in which both Ca and PTH are high), nonclassic (normohormonal or nonsuprese) pHPT (in which Ca is high and PTH is normal), normocalcemic pHPT (in which Ca is normal and PTH is high) biochemically. The only curative therapy for pHPT is parathyroidectomy. Parathyroidectomy is clearly indicated in all symptomatic patients. ''Fourth International Workshop on the Management of Asymptomatic pHPT'' had been performed in 2013. Surgical indications for pHPT are determined according to the age, Ca level, skeletal and renal findings. In some patients with asymptomatic disease, surgery is not mandatory. On the other hand, even in these patients who don't meet any criteria for parathyroidectomy, surgery is always an option because it is the only exact treatment for pHPT. The optimal treatment strategy for patients with normocalcemic pHPT has not yet been proved. Experts advise that patients be referred for parathyroidectomy if they have or progress complications of pHPT such as osteoporosis, fragility fractures or kidney stones, even if normocalcemia continues. Patients without complications at the time of diagnosis could be monitored for disease progression.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Owen R. On the anatomy of the Indian rhinoceros (Rh. Unicornis, L). Tran Zool Soc Lon 1862; 4: 31-58.
  • Sandstrom IV. On new gland in man and several mammals. English translation of "Glandulae Parathyreoidea," with biographical notes by Professor J August Hammar [Carl M. Seipel]. Bull Ins Hist Med 1938; 6: 179-222.
  • Weis N. Ueber Tetanie. Sammi Klin Vortr, 189. Inn Med 1881; 63: 1675-704 [in German].
  • Gley ME.Sur les fonctions du corps thyroide. C S Seances Soc Biol Fil 1891; 43: 8413 [in French].
  • Askanazy M. Ueber ostitis deformans ohne osteides Gewebe. Arb Pathol Inst Tubingen (Leipzig) 1904; 4: 398-422 [in German].
  • Erdheim J. Tetania parathyreopriva. Mitt Grenzgeb Med Chir 1906; 16: 632-744 [in German].
  • Maccallum WG, Voegtlin C. On the relation of tetany to the parathyroid glands and to calcium metabolism. J Exp Med 1909; 11: 118-51. [CrossRef]
  • Lal G, Clark OH. Thyroid, parathyroid, and adrenal. In: Brunicardi FC, Anderson DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, et al. Schwartz's Principles of Surgery. 10th ed. NewYork: McGraw Hill; 2015. pp.1522-96.
  • Schlagenhaufer F. Zwei falle von parathyroideatumoren. Wien Klin Wochenschr 1915; 28: 1362 [in German].
  • Hanson AM. An elementary chemical study of the parathyroid galnds of cattle. Mil surgeon 1923; 52: 280-4.
  • Colip JP. Extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the levels of blood calcium. J Biol Chem 1925; 63: 395-438.
  • Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am 2009; 89: 1205-25. [CrossRef]
  • Felger EA, Kandil E. Primary hyperparathyroidism. Otolaryngol Clin North Am 2010; 43: 417-32. [CrossRef]
  • Barr DP, Bulger HA, Dixon H. Hyperparathyroidism. JAMA 1929; 92: 951-2. [CrossRef]
  • Berson SA, Yalow RS, Aurbach GD, Potts JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci U S A 1963; 49: 613-7. [CrossRef]
  • Reiss E, Canterbury JM. A radioimmunoassay for parathyroid hormone in man. Proc Soc Exp Biol Med 1968; 128: 501-4. [CrossRef]
  • Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa- Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-7.
  • Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987; 65: 407-14. [CrossRef]
  • Irvin GL 3rd. American Association of Endocrine Surgeons. Presidential address: chasin' hormones. Surgery 1999; 126: 993- 7. [CrossRef]
  • Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non (1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: 805-9.
  • John M, Goodman W, Gao P, Cantor T, Salusky I, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implication for PTH measurements in renal failure. J Clin Endocrinol Metab 1999; 84: 4287-90. [CrossRef]
  • Gao P, Scheibel S, D'Amour P, John M, Rao S, Schmdt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-14. [CrossRef]
  • Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer 2014; 120: 3602-16. [CrossRef]
  • Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98: 1122-9. [CrossRef]
  • Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 2306-12. [CrossRef]
  • Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006; 21: 171-7. [CrossRef]
  • Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94: 335- 9. [CrossRef]
  • Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.J Clin Endocrinol Metab 2015; 100: 1309-15. [CrossRef]
  • Grant P, Velusamy A. What is the best way of assessing neurocognitive dysfunction in patients with primary hyperparathyroidism? J Clin Endocrinol Metab 2014; 99: 49-55. [CrossRef]
  • Bilezikian JP, Potts JT Jr. Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. J Bone Miner Res 2002;17 Suppl 2: N57- 67.
  • Applewhite MK, Schneider DF. Mild primary hyperparathyroidism: a literature review. Oncologist 2014; 19: 919-29. [CrossRef]
  • Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol 2011; 165: 851-64. [CrossRef]
  • Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-9. [CrossRef]
  • Marcocci C, Brandi ML, Scillitani A, Corbetta S, Faggiano A, Gianotti L, et al. Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism. J Endocrinol Invest 2015; 38: 577-93. [CrossRef]
  • Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 2036-40.
  • Castellano E, Tassone F, Attanasio R, Gianotti L, Pellegrino M, Borretta G. Mild primary hyperparathyroidism as defined in the Italian Society of Endocrinology's Consensus Statement: prevalence and clinical features. J Endocrinol Invest 2016; 39: 349-54. [CrossRef]
  • Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes 2015; 22: 413-21. [CrossRef]
  • Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94: 340-50. [CrossRef]
  • Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16: 33-9. [CrossRef]
  • Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-9. [CrossRef]
  • Pellitteri PK. Evaluation of hypercalcemia in relation to hyperparathyroidism. Otolaryngol Clin North Am 2010; 43: 389-97. [CrossRef]
  • Ong GS, Wlsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Cin Endocrinol Metab 2012; 97: 3138-45. [CrossRef]
  • Glendenning P, Gutteridge DH, Retallack RW, Stuckey BG, Kermode DG, Kent GN. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust N Z J Med 1998; 28: 173-8.
  • Wu JX, Yeh MW. Asymptomatic primary hyperparathyroidism. Diagnostic pitfalls and surgical Intervention. Surg Oncol Clin N Am 2016; 25: 77-90. [CrossRef]
  • Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98: 1122-9. [CrossRef]
  • Bergenfelz A, Lindblom P, Lindergård B, Valdemarsson S, Westerdahl J. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism. World J Surg 2003; 27: 481-5. [CrossRef]
  • Dy BM, Grant CS, Wermers RA, Keams AE, Huebner M, Harmsen WS, et al. Changes in bone mineral density after surgical intervention for primary hyperparathyroidism.Surgery 2012; 152: 1051-8. [CrossRef]
  • Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tİrring O et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007; 92: 1687-92. [CrossRef]
  • Ambrogini E, Cetani F, Cianferottti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Endocrinol Metab 2007; 92: 3114-21. [CrossRef]
  • Udelsman R, Åkerström G, Biagini C, Duh QY, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3595-606. [CrossRef]
  • Pasieka JL, Parsons LL. Prospective surgical outcome study of reliefof symptoms following surgery in patients with primary hyperparathyroidism. World J Surg 1998; 22: 513-8. [CrossRef]
  • Roman SA, Sosa JA, Pietrzak RH, Snyder PJ, Thomas DC, Udelsman R, et al. The effects of serum calcium band parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg 2011; 253: 131-7. [CrossRef]
APA Aygun N, ULUDAĞ M (2016). Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. , 171 - 180.
Chicago Aygun Nurcihan,ULUDAĞ Mehmet Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. (2016): 171 - 180.
MLA Aygun Nurcihan,ULUDAĞ Mehmet Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. , 2016, ss.171 - 180.
AMA Aygun N,ULUDAĞ M Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. . 2016; 171 - 180.
Vancouver Aygun N,ULUDAĞ M Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. . 2016; 171 - 180.
IEEE Aygun N,ULUDAĞ M "Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation." , ss.171 - 180, 2016.
ISNAD Aygun, Nurcihan - ULUDAĞ, Mehmet. "Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation". (2016), 171-180.
APA Aygun N, ULUDAĞ M (2016). Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. Şişli Etfal Hastanesi Tıp Bülteni, 50(3), 171 - 180.
Chicago Aygun Nurcihan,ULUDAĞ Mehmet Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. Şişli Etfal Hastanesi Tıp Bülteni 50, no.3 (2016): 171 - 180.
MLA Aygun Nurcihan,ULUDAĞ Mehmet Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. Şişli Etfal Hastanesi Tıp Bülteni, vol.50, no.3, 2016, ss.171 - 180.
AMA Aygun N,ULUDAĞ M Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. Şişli Etfal Hastanesi Tıp Bülteni. 2016; 50(3): 171 - 180.
Vancouver Aygun N,ULUDAĞ M Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation. Şişli Etfal Hastanesi Tıp Bülteni. 2016; 50(3): 171 - 180.
IEEE Aygun N,ULUDAĞ M "Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation." Şişli Etfal Hastanesi Tıp Bülteni, 50, ss.171 - 180, 2016.
ISNAD Aygun, Nurcihan - ULUDAĞ, Mehmet. "Primary Hyperparathyroidism: Current Situation in the Clinical and Biochemical Presentation". Şişli Etfal Hastanesi Tıp Bülteni 50/3 (2016), 171-180.